Esperion Therapeutics (ESPR) EBT (2012 - 2026)
Esperion Therapeutics (ESPR) posted EBT of -$26.4 million for Q1 2026, down 142.14% on a QoQ basis from $62.6 million in Q4 2025, and up 36.48% year-over-year from -$19.3 million in Q1 2025.
Esperion Therapeutics (ESPR) EBT (2012 - 2026) Analysis & Trends
Esperion Therapeutics' EBT history runs 15 years deep, the most recent figure standing at -$26.4 million for Q1 2026.
- Quarterly EBT rose 36.48% year-over-year to -$26.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.2 million (up 91.86% YoY) and the FY2025 annual result came in at -$20.8 million, up 59.72% from the prior year.
- EBT was -$26.4 million for Q1 2026 at Esperion Therapeutics, down from $62.6 million in the prior quarter.
- Across five years, EBT topped out at $62.6 million in Q4 2025 and bottomed at -$66.6 million in Q2 2022.
- A 5-year average of -$30.3 million and a median of -$41.5 million in 2025 frame the typical range for EBT.
- Peak annual rise in EBT reached 315.28% in 2025, while the deepest fall reached 171.3% in 2025.
- Esperion Therapeutics' EBT stood at -$56.8 million in 2022, then decreased by 1.02% to -$57.4 million in 2023, then soared by 49.36% to -$29.1 million in 2024, then soared by 315.28% to $62.6 million in 2025, then slumped by 142.14% to -$26.4 million in 2026.
- Business Quant data shows ESPR's EBT at -$26.4 million in Q1 2026, $62.6 million in Q4 2025, and -$32.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 437.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 758.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.90 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 318.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -247.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 246.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 87.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -26.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.38 Mn |
| Dec 31, 2025 | 62.60 Mn |
| Sep 30, 2025 | -32.01 Mn |
| Jun 30, 2025 | -13.39 Mn |
| Mar 31, 2025 | -41.53 Mn |
| Dec 31, 2024 | -29.08 Mn |
| Sep 30, 2024 | -31.11 Mn |
| Jun 30, 2024 | -11.14 Mn |
| Mar 31, 2024 | 58.25 Mn |
| Dec 31, 2023 | -57.42 Mn |
| Sep 30, 2023 | -42.53 Mn |
| Jun 30, 2023 | -51.60 Mn |
| Mar 31, 2023 | -62.99 Mn |
| Dec 31, 2022 | -56.84 Mn |
| Sep 30, 2022 | -55.78 Mn |
| Jun 30, 2022 | -66.64 Mn |
| Mar 31, 2022 | -57.05 Mn |
| Dec 31, 2021 | -69.06 Mn |
| Sep 30, 2021 | -69.40 Mn |
| Jun 30, 2021 | -43.68 Mn |